Thursday broker round-up
13th Oct 2016 13:43
(ShareCast News) - Ted Baker: Goldman Sachs keeps at buy with a target price of 3140p. Brown N: HSBC reiterates hold, 205p target. MITIE: Citigroup keeps at neutral with a 280p target. Prudential: Societe Generale reiterates outperform with a 1250p target. Astrazeneca: Jefferies keeps at buy with
Read moreSunday newspaper round-up: William Hill, Inflation, Ebay
9th Oct 2016 16:00
(ShareCast News) - William Hill and the Canadian owner of the PokerStars gaming website are in talks to create a £5bn betting giant that would storm into the FTSE 100. City sources said negotiations between Britain's biggest high-street bookmaker and Amaya, which bought PokerStars for $4.9bn two yea
Read moreAstraZeneca to divest US rights to nasal spray to J&J affiliate
7th Oct 2016 07:06
(ShareCast News) - Pharmaceutical giant AstraZeneca agreed to divest rights outside the US of its nasal spray to Johnson & Johnson affiliate CilagGmbH International for $330m in order to concentrate on respiratory treatments. AstraZeneca will not maintain an ongoing interest in the Rhinocort Aqua na
Read moreAstrazeneca wins Nice and beta-blocker deals but loses in Brilinta trial
4th Oct 2016 07:07
(ShareCast News) - It was two out of three for Astrazeneca on Tuesday as disappointment over the unsuccessful conclusion of a huge drug trial was offset by a win with the NHS drug regulator for one of its big cancer drugs and a licence deal for a beta-blocker medicine. Dealing with the bad news firs
Read moreTuesday newspaper round-up: AstraZeneca, rental housing, BT, BP
4th Oct 2016 06:57
(ShareCast News) - AstraZeneca has won a major victory in the UK after the country's drugs watchdog approved one of the most important cancer drugs in its oncology portfolio. The National Institute for Health and Care Excellent (Nice) announced on Tuesday that osimertinib, known under the brand name
Read moreAstraZeneca signs drug deal with Allergan
3rd Oct 2016 07:29
(ShareCast News) - AstraZeneca's global biologics research and development arm MedImmune has entered into a licensing agreement with Allergan for the global rights to MEDI2070, which is currently in a Phase IIb clinical trial for moderate-to-severe Crohn's disease and ready for Phase II for ulcerati
Read moreWednesday broker round-up
28th Sep 2016 12:15
(ShareCast News) - Close Brothers Group: Barclays reiterates overweight with a target price of 1500p. Royal Dutch Shell: HSBC keeps at buy, 2050p target. William Hill: Deutsche Bank keeps at buy with a 390p target. The Restaurant Group: Berenberg reiterates hold with a 350p target. Astrazeneca: D
Read moreMonday broker round-up
19th Sep 2016 09:52
(ShareCast News) - Lloyds: Jefferies reiterates buy with a target price of 67p. Astrazeneca: UBS reiterates buy, 5480p target. Britvic: JP Morgan keeps at underweight with a 590p target. Unilever: UBS reiterates neutral with a 3380p target. IHG: HSBC starts coverage at reduce with a 2900p target.
Read moreBroker tips: Pets at Home, Wood Group, Astrazeneca
12th Sep 2016 11:03
(ShareCast News) - Citigroup initiated coverage of Pets at Home at 'buy' with a 275p price target, given its expectation of the medium-term margin upside opportunity and cash returns. The bank reckons that over the next 10 years, the vet business could generate an incremental £40m earnings before in
Read moreMonday broker round-up
12th Sep 2016 09:24
(ShareCast News) - Autotrader: Barclays reiterates equal-weight with a target price of 375p. Hikma: Jefferies maintains buy with a 2500p target. Wood Group: Exane BNP Paribas upgrades to buy with a 815p target. Man Group: Citigroup upgrades to buy with a 137p target. McCarthy & Stone: Goldman Sac
Read moreJefferies upgrades AstraZeneca to 'buy'
12th Sep 2016 07:34
(ShareCast News) - Jefferies upgraded AstraZeneca to 'buy' from 'hold' and lifted the price target to 5,800p from 5,400p saying it sees a much higher probability of success and larger market opportunity from the MYSTIC study than consensus implies. The MYSTIC study is a global, phase 3 study of the
Read moreConsort Medical signs agreement with AstraZeneca
7th Sep 2016 08:43
(ShareCast News) - Consort medical, a provider of advanced technology for drugs, has signed a new contract with pharmaceutical giant AstraZeneca for the supply of its Bespak respiratory devices. AstraZeneca and Bespak have agreed to enter into a multi-year agreement for the scale-up and supply of Be
Read moreSector movers: Vodafone weighs on mobile telecoms
1st Sep 2016 21:10
(ShareCast News) - News that CK Hutchison Holdings and VimpelCom had won European Union approval to merge, in the process creating Italy´s biggest wireless telecommunications provider, sent stock in Vodafone sharply lower and its sector gauge with it. Vodafone´s own unit in that Mediterranean countr
Read moreAstraZeneca offloads anaesthetic rights to Aspen
1st Sep 2016 07:41
(ShareCast News) - AstraZeneca announced on Thursday morning that it has completed its commercialisation agreement with Aspen Global Incorporated, for rights to its global anaesthetics portfolio outside the US. The FTSE 100 pharmaceutical firm said the agreement covers seven established medicines -
Read moreThursday newspaper share tips: WPP and Astrazeneca
25th Aug 2016 14:47
(ShareCast News) - The mood in advertising giant WPP should be pretty good, opines Financial Times' Lex column, which, in something of a novelty, cites Martin Sorrell's healthy tan. Something to do with enhanced moods due to the sun and serotonin release, the column wheezed. It noted that, as was t
Read more